Abstract Factors predisposing to the phenotypic features of familial combined hyperlipidemia have not been clearly defined. In the course of investigating familial coronary artery disease in Utah, we identified a three-generation family in which multiple members were affected with type IIa hyperlipoproteinemia (HLP IIa), type IIb hyperlipoproteinemia (HLP IIb), or type IV hyperlipoproteinemia (HLP IV). Because several family members had relatively severe low-density lipoprotein (LDL) cholesterol elevation, in order to dissect the possible contribution to the plasma lipoprotein abnormalities in this pedigree, we identified a novel point mutation in the low-density lipoprotein receptor (LDLR) gene, a G-to-A transition at nucleotide position 337 in exon 4. This change substituted lysine for glutamic acid at codon 92 (D92K) of the LDL receptor. By means of mutant allele-specific amplification we determined that the mutation co-segregated with elevated cholesterol and LDL cholesterol in the plasma of family members with HLP IIa and HLP IIb, but not with the elevated plasma triglycerides seen in HLP IIb and HLP IV patients. Thus, in families with apparent familial combined hyperlipidemia, a defective LDLR allele and other genetic or environmental factors that elevate plasma triglycerides may account for the multiple lipid phenotypes observed in this kindred.
Introduction
Lipid and lipoprotein concentrations in plasma reflect, in part, the influence of multiple genetic loci (Zannis and Breslow 1985; Breslow 1987) , in which defects are known to account for some types of hyperlipoproteinemia (HLP) that affect multiple members of certain families. However, the genetic mechanisms responsible for most types of familial dyslipoproteinemia appear to be complex, not monogenic. For instance, one of the most common forms of hyperlipidemia is familial combined hyperlipidemia (Goldstein et al. 1973) . The features of familial combined hyperlipidemia include moderate elevation of plasma cholesterol, or triglycerides, or both, within individuals of an affected kindred. Familial combined hyperlipidemia should be suspected in subjects with moderate hypertriglyceridemia and/or moderate hypercholesterolemia (lipoprotein types IIa, IIb, or IV), especially in the setting of a family history of premature coronary heart disease. The diagnosis is a clinical one; it requires demonstration of the clinical phenotype in the affected individuals and family members (Mahley et al. 1998) . In spite of the apparent strong predisposition to coronary artery diseases that this condition confers, whether the multiple lipoprotein patterns observed in such kindreds result from the inheritance of a single autosomal dominant allele or from multiple, distinct familial conditions cannot be clearly resolved in the absence of specific genetic markers. Yet in some families in which affected members show lipoprotein lipase (LPL) deficiency, relatives of a homozygous proband have been described with type I, type IIa, type IIb, type IV, or type V HLP (Berger and Bonnici 1977; Gagne et al. 1977; Wilson et al. 1983 ). These observations have led to the suggestion that heterozygosity for a mutant LPL gene may be a predisposing component for the expression of familial combined hyperlipidemia (Wilson et al. 1983; Babirak et al. 1989) .
We ascertained a three-generation pedigree in Utah, designated K450, in which 15 members were affected with hyperlipoproteinemia but exhibited various lipoprotein profiles. Lipoprotein analyses identified 9 individuals with type IIa hyperlipoproteinemia (HLP IIa; LDL cholesterol, Ͼ90th percentile; normal plasma triglycerides), 3 with type IIb hyperlipoproteinemia (HLP IIb; both LDL cholesterol and plasma triglycerides, Ͼ90th percentile), and 3 with type IV hyperlipoproteinemia (HLP IV; plasma triglycerides, Ͼ90th percentile; normal LDL cholesterol). This pedigree therefore provided an opportunity to begin dissecting a disease by analyzing genetic variations at a candidate gene involved in lipoprotein metabolism, the LDL receptor (Goldstein et al. 1995) .
Materials and methods

Patients and lipoprotein measurement
Participants in this study were members of a single pedigree that were seen at the Cardiovascular Genetics Research Clinic of the University of Utah. After they had fasted for 12-16 h, untreated blood samples were collected from all 24 participating family members. Lipid and lipoprotein concentrations were measured by procedures described previously (Wu et al. 1989) . In brief, plasma cholesterol and triglyceride concentrations were assayed enzymatically, concentrations of high-density lipoprotein cholesterol (HDL-c) were determined by MgCl 2 -dextran precipitation, and plasma lipoproteins were centrifuged in a Beckman TL-100 tabletop ultracentrifuge (Beckman, CA, USA) for 4 h at 60,000 rpm at room temperature, and thereafter separated into top (very low-density lipoprotein; VLDL) and bottom (LDL plus HDL) fractions by tube slicing. This method was important in the differential diagnosis of HLP III from other types of HLPs.
Single-strand conformational polymorphism (SSCP) analysis and DNA sequencing Initial polymerase chain reactions (PCRs) were carried out using 20 ng of genomic DNA extracted from lymphocytes, each in a 10-µl aliquot of solution containing 10mM TrisHCl (pH 8.4), 50 mM KCl, 1.5mM MgCl 2 , 0.01% gelatin, 200 µM of each dNTP, 2µCi of [alpha 32 P]-dCTP (3,000Ci/ mmol, 10 mCi/ml), 2.5 pmol of each primer, and 0.25 units of Taq polymerase (Tsukamoto et al. 1998) . PCR primers for amplification of each exon of the LDLR gene and all its exon-intron boundaries were described by Leitersdorf et al. (1990) or by Leren et al. (1993) . Each of 35 PCR cycles consisted of 30 s at 94°C, 30 s at 71°C, and 30 s at 72°C. Reaction mixtures were diluted with 50 µl of 95% formamide dye and 20 mM ethylenediamine tetraacetic acid (EDTA), incubated at 85°C for 5 min, and applied (2 µl/ lane) to 6% polyacrylamide gels containing 0.5ϫ TBE (90 mM Tris-borate/2 mM EDTA) and 5% glycerol. Electrophoresis was performed both at room temperature and at 4°C (Hirayama et al. 1998 ). The gels were dried and autoradiographed with intensifying screens. When a variant band was revealed by SSCP analysis, the corresponding DNA fragment was sequenced directly on both strands to identify the nature of the mutation. Each result was confirmed by two independent experiments. Mutant allele-specific amplification (MASA) Genomic DNA was extracted from lymphocytes of 17 family members. PCR amplifications were carried out using 20ng of genomic DNA, 10 mM of Tris-HCl (pH 8.4), 50 mM of KCl, 1.5 mM of MgCl 2 , 0.01% gelatin, 200 µM of each dNTP, 2.5 pmol each of mismatched primer (5Ј-TCGGCCATCCATCCCTGCAG-3Ј) on one side and normal primer (anti-sense: 5Ј-CTGCGGCCACTCATCC-GAGC-3Ј) on the other side, and 0.25 units of Taq polymerase, in a volume of 10µl (Hopkins et al. 1999) . Cycle conditions were 94°C for 3.5min, then 30 cycles of 94°C for 30s, 71°C for 30 s, and 72°C for 30 s, with a final extension step of 3.5 min at 72°C, in a Gene Amp PCR 9600 System (PE Biosystems, Foster City, CA, USA). PCR products were electrophoresed in 3% agarose gels and visualized by ethidium-bromide staining.
Statistical analysis
Plasma lipoprotein levels in individuals who possessed the mutant LDLR allele and in individuals who did not were compared using non-parametric (Student-Newman-Keuls) analysis. Differences in means were considered statistically significant at P values Ͻ0.05.
Results
The pedigree structure of K450, and the ages and untreated lipoprotein profiles of all 24 members examined, are shown in Fig. 1 . Nine members of the family exhibited the lipoprotein phenotype of HLP IIa, three that of HLP IIb, and 3, that of HLP IV, suggesting a diagnosis of familial combined hyperlipidemia. The proband was a 43-year-old Caucasian woman (individual II-3; Fig. 1 ) who was diagnosed with HLP IIb. The elevated LDL cholesterol (LDL-c) levels common in her family appeared to follow a Mendeliandominant mode of inheritance when treated as a single trait, which led us to suspect segregation of a defective LDL receptor allele in this family.
When we screened the proband's genomic DNA for mutation of the LDLR gene, we identified an aberrant SSCP pattern in the PCR product of exon 4 (Fig. 2a) . Direct sequencing on both strands revealed heterozygosity for a Gto-A transition at nucleotide position 337 of the LDLR cDNA. This transition would substitute lysine for glutamic acid at codon 92 (D92K; Fig. 2b ). D92K was the only sequence variation detected in the entire coding region or splice-site consensus sequences.
Diagnosis of the D92K mutation was carried out by mutant allele-specific ampification (MASA) in all 17 members of the proband's family from whom genomic DNA was available. Representative results are shown in Fig. 3 . The MASA test detected mutant alleles of LDLR in 8 individuals. These individuals contained at least one mutant allele. The other 9 people were excluded from carrier status ( Table 1 ). The mean (ϮSD) values for total cholesterol (TC), plasma triglyceride, LDL cholesterol, and HDL cholesterol are illustrated by histograms in Fig. 4 . In mutation carriers, total cholesterol and LDL-c levels were significantly increased (P Ͻ 0.003 for TC; P Ͻ 0.0001 for LDL-c) compared with levels in non-carriers, whether or not the II-2  44  222  94  50  159  23  II-4  46  223  164  48  74  28  II-6  35  200  316  36  101  79  II-9  50  131  59  45  127  8  III-1  21  200  103  57  127  22  III-6  9  252  103  64  157  27  III-8  22  222  107  44  139  28  III-10  7  213  172  45  129  29  III-13  5  116  66  56  101  11  Average  27  203  132  49  127  28 No., Corresponds to family members shown in the pedigree in Fig. 1 TC, Total cholesterol; TG, plasma triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; VLDL, very low-density lipoprotein cholesterol carriers had presented with either HLP IIa or HLP IIb. However, triglyceride (TG) and HDL-c levels did not differ significantly between carriers and non-carriers of the LDLR mutation (P ϭ 0.265 for TG; P ϭ 0.400 for HDL-c).
Among the 17 genotyped members, all HLP IIa and HLP IIb patients carried the D92K mutation, but neither of the two HLP IV patients did. These data were evidence that elevated levels of total and LDL cholesterol reflected inheritance of the D92K mutation of the LDLR gene in K450, while plasma triglyceride and HDL cholesterol levels did not.
Discussion
In this study we examined a kindred with multiple lipoprotein abnormalities. As this family was notable for lack of consanguinity and lack of confounding valuables such as smoking or abuse of alcohol, it provided a unique test population for clarifying genetic components associated with apparent familial combined hyperlipidemia. The phenotype associated with inheritance of the D92K mutation of LDLR in this kindred was elevated plasma levels of total cholesterol and LDL-cholesterol; this phenotype alone was transmitted in an autosomal dominant fashion.
Two hypotheses for the genetic mechanism of familial combined hyperlipidemia, either the "single-gene hypothesis" or the "multiple-gene hypothesis" were tested in the present study. Through genetic analysis, we showed that one of the prominent phenotypes, elevated LDL cholesterol, segregated with genetic defect at one locus (LDLR), but the other characteristic phenotype, elevated plasma triglycerides, did not co-segregate with that locus. This explains the presence of members with a normal LDLR allele having HLP IV. Thus, elevated plasma triglycerides was most likely to be explained by an unknown factor, genetic or environmental. These data are consistent with the "multiple-gene hypothesis" for familial combined hyperlipidemia etiology, at least in this pedigree. We previously reported four hyperlipidemic extended pedigrees with a complex lipoprotein phenotype, and showed that elevated LDL cholesterol concentrations in that family also were due to a defective LDLR gene. Furthermore, we showed that HLP III occurred among individuals who inherited a defective LDLR allele and also a defective allele of the apolipoprotein E gene (apoE2). The latter allele had a striking effect on remnant accumulation, expressed as the VLDL cholesterol-to-plasma triglyceride ratio only among individuals who also carried defective LDLR alleles Hopkins et al. 1991) . That study provided an early example of genetic interactions resulting in the manifestation of a separate lipoprotein abnormality.
Attention has been focused recently on the influence of lipoprotein lipase (LPL) and cholesteryl ester transfer protein (CETP) on plasma HDL-cholesterol levels in carriers of mutant LDLR alleles, when heterozygotes for defective LDL receptors also carry mutations of either LPL or CETP (double heterozygotes). Pimstone et al. (1995) noted that mutations that reduced LPL activity were associated with lower HDL-cholesterol levels in familial hypercholesterolemia (FH)-heterozygotes, and suggested a positive relationship. On the other hand, mutant alleles of CETP were associated with increased HDL-cholesterol levels in Japanese patients with heterozygous FH (Haraki et al. 1997) ; however, the high HDL-cholesterol levels did not appear to protect these double heterozygotes in this population from the development of coronary heart disease.
Some familial combined hyperlipidemias in various kindreds may reflect genetic interactions among defective LDLR genes, mutant LPL genes, or common but unidentified alleles of other genes involved in lipid metabolism. Thus, if a defective LDL receptor allele was to segregate independently but concurrently with an allele directing increased plasma triglyceride levels, the observed phenotype might resemble familial combined hyperlipidemia. The effect of interactions between mutant LDLR alleles and alleles of other common lipid-related genes remains to be investigated.
The frequency with which defects in the LDLR are involved in the pathogenesis of familial combined hyperlipidemia is not known at present. The observations reported here provide independent genetic evidence for the existence of a subset of patients who carry combinations of defects in several aspects of lipoprotein metabolism. These findings underscore the potential complexity among genetic factors, and probably environmental factors, that leads to the manifestation of familial combined hyperlipidemia. Our results suggest that unidentified genes are influencing the observed phenotypes. Indeed, we expect that multiple gene effects, both additive and interacting, will eventually prove to be responsible for many cases of common, inherited, mixed dyslipidemias.
